Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced ...

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line ...

Merck gets US FDA approval for Keytruda plus pemetrexed & platinum chemotherapy to treat unresectable advanced or metastatic MPM: Rahway, New Jersey Thursday, September 19, 2024, ...

The annual overnight camping trip for Mettawee sixth graders does not go unnoticed by the rest of the students. “We saw how ...

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Merck, a leading science and technology company, and Siemens deepened their cooperation aimed at taking smart manufacturing ...

Headlines,Wall Street analysts show strong enthusiasm for Merck, (NYSE:MRK),, with the average brokerage recommendation (ABR) ...

Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...

(Reuters) - A U.S. appeals court revived a lawsuit on Friday by healthcare and drug industry groups challenging the ...